{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:26:38Z","timestamp":1790061998301,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019851","name":"Aldeyra Therapeutics","doi-asserted-by":"crossref","award":["No award number"],"award-info":[{"award-number":["No award number"]}],"id":[{"id":"10.13039\/100019851","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s40123-022-00520-z","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T18:02:50Z","timestamp":1652896970000},"page":"1449-1461","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial"],"prefix":"10.1007","volume":"11","author":[{"given":"Bill","family":"Cavanagh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E.","family":"Starr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly K.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd C.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"issue":"6","key":"520_CR1","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/cea.12536","volume":"45","author":"A Leonardi","year":"2015","unstructured":"Leonardi A, Piliego F, Castegnaro A, et al. Allergic conjunctivitis: a cross-sectional study. Clin Exp Allergy. 2015;45(6):1118\u201325.","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"520_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/00002018-200225010-00004","volume":"25","author":"CN McGhee","year":"2002","unstructured":"McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 2002;25(1):33\u201355.","journal-title":"Drug Saf"},{"issue":"4","key":"520_CR3","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jaci.2010.06.050","volume":"126","author":"K Singh","year":"2010","unstructured":"Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988\u20131994. J Allergy Clin Immunol. 2010;126(4):778\u201383.e6.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"520_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1042\/BJ20111752","volume":"442","author":"A Higdon","year":"2012","unstructured":"Higdon A, Diers AR, Oh JY, Landar A, Darley-Usmar VM. Cell signalling by reactive lipid species: new concepts and molecular mechanisms. Biochem J. 2012;442(3):453\u201364.","journal-title":"Biochem J"},{"issue":"5","key":"520_CR5","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1189\/jlb.1211617","volume":"92","author":"S Raghavan","year":"2012","unstructured":"Raghavan S, Subramaniyam G, Shanmugam N. Proinflammatory effects of malondialdehyde in lymphocytes. J Leukoc Biol. 2012;92(5):1055\u201367.","journal-title":"J Leukoc Biol"},{"issue":"10","key":"520_CR6","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1089\/jop.2020.0056","volume":"36","author":"KJ Mandell","year":"2020","unstructured":"Mandell KJ, Clark D, Chu DS, Foster CS, Sheppard J, Brady TC. Randomized phase 2 trial of reproxalap, a novel reactive aldehyde species inhibitor, in patients with noninfectious anterior uveitis: model for corticosteroid replacement. J Ocul Pharmacol Ther. 2020;36(10):732\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"520_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1089\/jop.2020.0087","volume":"37","author":"D Clark","year":"2021","unstructured":"Clark D, Sheppard J, Brady TC. A randomized double-masked phase 2a trial to evaluate activity and safety of topical ocular reproxalap, a novel RASP inhibitor, in dry eye disease. J Ocul Pharmacol Ther. 2021;37(4):193\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"key":"520_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ajo.2021.01.011","volume":"226","author":"D Clark","year":"2021","unstructured":"Clark D, Tauber J, Sheppard J, Brady TC. Early onset and broad activity of reproxalap in a randomized, double-masked, vehicle-controlled phase 2b trial in dry eye disease. Am J Ophthalmol. 2021;226:22\u201331.","journal-title":"Am J Ophthalmol"},{"key":"520_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ajo.2021.04.023","volume":"230","author":"D Clark","year":"2021","unstructured":"Clark D, Cavanagh B, Shields AL, Karpecki P, Sheppard J, Brady TC. Clinically relevant activity of the novel RASP inhibitor reproxalap in allergic conjunctivitis: the phase 3 ALLEVIATE trial. Am J Ophthalmol. 2021;230:60\u20137.","journal-title":"Am J Ophthalmol"},{"key":"520_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/OPTH.S345324","volume":"16","author":"D Clark","year":"2022","unstructured":"Clark D, Karpecki P, Salapatek AM, Sheppard JD, Brady TC. Reproxalap improves signs and symptoms of allergic conjunctivitis in an allergen chamber: a real-world model of allergen exposure. Clin Ophthalmol. 2022;16:15\u201323.","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"520_CR11","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/S0149-2918(04)80065-1","volume":"26","author":"MB Abelson","year":"2004","unstructured":"Abelson MB, Gomes PJ, Vogelson CT, et al. Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study. Clin Ther. 2004;26(8):1237\u201348.","journal-title":"Clin Ther"},{"key":"520_CR12","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.2147\/OPTH.S83263","volume":"9","author":"G Torkildsen","year":"2015","unstructured":"Torkildsen G, Narvekar A, Bergmann M. Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model. Clin Ophthalmol. 2015;9:1703\u201313.","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"520_CR13","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1586\/14737167.2015.1115348","volume":"15","author":"A Shields","year":"2015","unstructured":"Shields A, Coon C, Hao Y, et al. Patient-reported outcomes for US oncology labeling: review and discussion of score interpretation and analysis methods. Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):951\u20139.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"520_CR14","unstructured":"US Food and Drug Administration. Guidance for Industry\u2014Patient-reported outcome measures: use in medical product development to support labeling claims. Published 2009. https:\/\/www.fda.gov\/media\/77832\/download. Accessed April 27, 2022."},{"key":"520_CR15","unstructured":"US Food and Drug Administration. Patient-Focused Drug Development Guidance Public Workshop: Incorporating clinical outcome assessments into endpoints for regulatory decision-making. Held December 6, 2019. https:\/\/www.fda.gov\/media\/132505\/download. Accessed April 27, 2022."},{"issue":"4","key":"520_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1081-1206(10)61155-6","volume":"95","author":"W Berger","year":"2005","unstructured":"Berger W, Abelson MB, Gomes PJ, et al. Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy. Ann Allergy Asthma Immunol. 2005;95(4):361\u201371.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"520_CR17","unstructured":"Mroz M, Shapiro SA, Abelson MB. Development of the Allergic Conjunctivitis Quality of Life Questionnaire (ACQLQ). Presented at DIA 9th Annual Symposium for Quality of Life Evaluations. Hilton Head, SC, USA; 2002."},{"key":"520_CR18","unstructured":"American Academy of Allergy, Asthma and Immunology. Reading the levels. https:\/\/pollen.aaaai.org\/#\/pages\/reading-the-levels. Accessed February 23, 2022."},{"issue":"12","key":"520_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v050.i12","volume":"50","author":"K Noguchi","year":"2012","unstructured":"Noguchi K, Gel YR, Brunner E, Konietschke F. nparLD: an R Software package for the nonparametric analysis of longitudinal data in factorial experiments. J Stat Softw. 2012;50(12):1\u201323.","journal-title":"J Stat Softw"},{"issue":"4","key":"520_CR20","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ejvs.2015.12.012","volume":"51","author":"AP Conijn","year":"2016","unstructured":"Conijn AP, Bipat S, Reekers JA, Koelemay MJ. Determining the minimally important difference for the VascuQol Sumscore and its domains in patients with intermittent claudication. Eur J Vasc Endovasc Surg. 2016;51(4):550\u20136.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"3","key":"520_CR21","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3945\/ajcn.115.120378","volume":"103","author":"LD McLeod","year":"2016","unstructured":"McLeod LD, Cappelleri JC, Hays RD. Best (but oft-forgotten) practices: expressing and interpreting associations and effect sizes in clinical outcome assessments. Am J Clin Nutr. 2016;103(3):685\u201393.","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"520_CR22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/cncr.22799","volume":"110","author":"J Ringash","year":"2007","unstructured":"Ringash J, O\u2019Sullivan B, Bezjak A, Redelmeier DA. Interpreting clinically significant changes in patient-reported outcomes. Cancer. 2007;110(1):196\u2013202.","journal-title":"Cancer"},{"issue":"5","key":"520_CR23","first-page":"582","volume":"41","author":"GR Norman","year":"2003","unstructured":"Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582\u201392.","journal-title":"Med Care"},{"issue":"5","key":"520_CR24","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/00005650-199905000-00006","volume":"37","author":"KW Wyrwich","year":"1999","unstructured":"Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care. 1999;37(5):469\u201378.","journal-title":"Med Care"},{"issue":"6","key":"520_CR25","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/SPV.0000000000000078","volume":"20","author":"JE Jelovsek","year":"2014","unstructured":"Jelovsek JE, Chen Z, Markland AD, et al. Minimum important differences for scales assessing symptom severity and quality of life in patients with fecal incontinence. Female Pelvic Med Reconstr Surg. 2014;20(6):342\u20138.","journal-title":"Female Pelvic Med Reconstr Surg"},{"issue":"4","key":"520_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1046\/j.0962-1105.2003.00365.x","volume":"12","author":"N Zisapel","year":"2003","unstructured":"Zisapel N, Nir T. Determination of the minimal clinically significant difference on a patient visual analog sleep quality scale. J Sleep Res. 2003;12(4):291\u20138.","journal-title":"J Sleep Res"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-022-00520-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-022-00520-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-022-00520-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T16:03:52Z","timestamp":1656950632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-022-00520-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["520"],"URL":"https:\/\/doi.org\/10.1007\/s40123-022-00520-z","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"assertion":[{"value":"23 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}